Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jun, Heungman | - |
dc.contributor.author | Kim, Myung Gyu | - |
dc.contributor.author | Jung, Cheol Woong | - |
dc.date.accessioned | 2021-09-04T03:19:07Z | - |
dc.date.available | 2021-09-04T03:19:07Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-02 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89588 | - |
dc.description.abstract | Purpose: For the past decades, the long-term results of renal allograft unchanged despite the development of immunology and drugs. The long-term use of a calcineurin-inhibitor (CNI) and medication nonadherence have become important issues affecting long-term results. The combination of the once-daily advagraf and sirolimus was proposed as a good alternative with such reasons. The purpose of this study was the analysis of the clinical advantages of once daily advagraf and sirolimus combination by decreasing the use of CM and improving medication adherence in stable kidney recipients. Materials and methods: In this study, 34 patients who switched from their present medication to a once-daily advagraf and sirolimus combination at Korea University Anam Hospital from September 2011 to March 2013 were retrospectively reviewed for 24 months. Laboratory findings, clinical findings, and medication adherence were reviewed and analyzed. Results: After conversion to the new regimen, renal function was slightly improved at 3 months, as evidenced by creatinine levels (p = 0.024) and eGFR (p < 0.001). Lipid profiles deteriorated throughout the study period. Serum fast glucose level and proteinuria increased significantly at 12 months but recovered at 24 months. On the Morisky-Green test (MGT) for medication adherence, there were adherent improvements of 23.33% after 12 months and 16.66% after 24 months. Conclusion: The once-daily advagraf and sirolimus combination can be a safe and effective regimen in stable kidney recipients as the study shows that the regimen improves renal function and medication adherence with controllable adverse effects of sirolimus. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.subject | RENAL-TRANSPLANT RECIPIENTS | - |
dc.subject | CONTROLLED-TRIAL | - |
dc.subject | GRAFT-SURVIVAL | - |
dc.subject | TACROLIMUS | - |
dc.subject | NONADHERENCE | - |
dc.subject | INHIBITORS | - |
dc.subject | RAPAMYCIN | - |
dc.subject | IMMUNOSUPPRESSION | - |
dc.subject | OPPORTUNITY | - |
dc.subject | EXPOSURE | - |
dc.title | Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Myung Gyu | - |
dc.contributor.affiliatedAuthor | Jung, Cheol Woong | - |
dc.identifier.doi | 10.5414/CP202518 | - |
dc.identifier.scopusid | 2-s2.0-84958794143 | - |
dc.identifier.wosid | 000371375100001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.54, no.2, pp.81 - 86 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 54 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 81 | - |
dc.citation.endPage | 86 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | RENAL-TRANSPLANT RECIPIENTS | - |
dc.subject.keywordPlus | CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | GRAFT-SURVIVAL | - |
dc.subject.keywordPlus | TACROLIMUS | - |
dc.subject.keywordPlus | NONADHERENCE | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | RAPAMYCIN | - |
dc.subject.keywordPlus | IMMUNOSUPPRESSION | - |
dc.subject.keywordPlus | OPPORTUNITY | - |
dc.subject.keywordPlus | EXPOSURE | - |
dc.subject.keywordAuthor | medication adherence | - |
dc.subject.keywordAuthor | advagraf and sirolismus combination | - |
dc.subject.keywordAuthor | renal transplantation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.